DelveInsight’s ‘Endometriosis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Endometriosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Endometriosis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan
Study Period: 2016-2027
Endometriosis - Disease Understanding and Treatment Algorithm The DelveInsight Endometriosis market report gives the thorough understanding of the Endometriosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Endometriosis in the US, Europe, and Japan. Endometriosis Epidemiology The Endometriosis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total prevalence, diagnosed population and treatable cases of Endometriosis in 7MM. According to DelveInsight, the prevalent cases of Endometriosis in 7 major markets was 13.8 Million in 2016 and, is expected to increase at a significant growth rate during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of Endometriosis i.e., 7.4 Million followed by United Kingdom.
Endometriosis Drug Chapters This segment of the Endometriosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline products. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The marketed drugs available for the treatment of Endometriosis mainly include Lupron (Abbvie), Visanne/Dienogest (Bayer Healthcare), Zoladex (AstraZeneca), Synarel (Pfizer) and Depo-SubQ. Detailed chapters for all of these drugs, along with the promising upcoming therapies such as Elagolix (Abbvie), Femitra (Endooceutics) etc. have been covered in the report.
Endometriosis Market Outlook The Endometriosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the global market [that includes 7MM, Rest of Europe (RoE) and Rest of World (RoW)] of Endometriosis was USD 1,856 Million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.
Endometriosis Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Endometriosis Report Insights • Patient Population • Therapeutic Approaches • Pipeline Analysis • Market Size and Trends • Market Opportunities • Impact of upcoming Therapies
Key Benefits • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Endometriosis market • Organize sales and marketing efforts by identifying the best opportunities for Endometriosis market • To understand the future market competition in the Endometriosis market.
Our reports have been used by over 10K customers, including:
Introduction “Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Uterine Leiomyoma (Uterine Fibroids) . The report includes information of marketed products including their product...
Renal Diseases Drug Development Pipeline Review, 2018 Summary Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The...
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 220.127.116.11)...
DelveInsight’s ‘Acute Renal Failure (ARF)- Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Acute Renal Failure in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. Geography Covered • The United States •...
Endometriosis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2018, provides an overview of the Endometriosis (Women’s Health) pipeline landscape. Endometriosis is an often painful disorder...
158 pages •
By Roots Analysis Private Ltd.
• Nov 2018
INTRODUCTION Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over...
Amenorrhea Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Amenorrhea Global Clinical Trials Review, H2, 2018" provides an overview of Amenorrhea clinical trials scenario.This report provides top line data relating to the clinical trials on Amenorrhea. Report...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.